VolitionRx reports FY2023 revenue up 153% to $775K; cash $20.7M

VOLITIONRX LTD

Revenue of ~$775K in FY2023, up 153% YoY; net cash used in operations $18.1M.
Cash & equivalents $20.7M at Dec 31, 2023 (vs $10.9M end of 2022); received $13.0M milestone from Heska in Dec 2023.
Sold kits for over 58,000 Nu.Q Vet Cancer Tests in 2023; new partnerships including Fujifilm Vet Systems; in-house test via Heska/Antech coming soon.
Nu.Q NETs pillar advanced with FDA regulatory pathway; Capture-PCR breakthrough presented at ESMO 2023.
Conference call March 26, 2024 at 8:30 AM ET.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

VOLITIONRX LTD reported the full fiscal year ended December 31, 2023 results: revenue approximately $775,000.

Period: the full fiscal year ended December 31, 2023
Revenue: approximately $775,000
Result: reported results

Exact text from the filing

· Cash and cash equivalents as of December 31, 2023, totaled approximately $20.7 million as compared to $10.9 million as of December 31, 2022. · Recorded approximately $775,000 in revenue in 2023, up 153% over the prior year. · Received $13.0 million in milestone payments from Heska Corporation in December 2023. · Net cash used in operating activities

View on SEC.gov

326 earnings releases filed in the last 30 days. Browse all earnings releases →

VOLITIONRX LTD filing history →

Source: SEC EDGAR

accession 0001477932-24-001451

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.